Contineum Therapeutics Stock

contineum-tx.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $133.61MM

Contineum is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need.

Register To Buy and Sell Shares

For more details on financing and valuation for Contineum Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Contineum Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Contineum Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

News Highlights

Pipeline Therapeutics and Janssen partner for neuroscience therapy
"Pipeline Therapeutics and Janssen Pharmaceutical have partnered to develop PIPE-307, a potential treatment for disorders of the nervous system. Janssen will receive an exclusive global licence for the research, development and commercialisation of PIPE-307, while Pipeline will have the right to advance the therapy into a Phase II clinical trial. Janssen will make an upfront payment of $50m to Pipeline and Pipeline will receive $1bn in milestones, along with royalty payments.
Updated on: Apr 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.